

## Rotundifolides A and B, Two New Enol-Derived Butenolactones from the Bark of *Litsea rotundifolia* var. *oblongifolia*

by Ya Zhao, Yue-Wei Guo\*, and Wen Zhang

State Key Laboratory of Drug Research, Institute of Materia Medica, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Zu Chong Zhi Rd. 555, Zhangjiang High-Tech Park, Shanghai 201203, P. R. China (phone: 86-21-50805813; e-mail: ywguo@mail.shnc.ac.cn)

---


Two new enol-derived butenolactones, rotundifolides A (**1**) and B (**2**), along with four known related compounds, lincomolide C (**3**), lincomolide A (**4**), marliolide (**5**), and litsenolide A<sub>1</sub> (**6**), were isolated from the bark of *Litsea rotundifolia* var. *oblongifolia*. The structures of the new metabolites were characterized by spectroscopic methods and comparison with known compounds.

---

**Introduction.** – *Litsea* is a genus in the family Lauraceae with *ca.* 72 species distributed in South and Southwest China [1]. Most *Litsea* plants contain alkaloids [2–4], flavonoids [5][6], terpenes [7][8], lactones [9], and volatile oil [10], which were reported to possess a variety of biological activities ranging from antimicrobial, hypothermic, to antitumor activities [2][11][12]. In continuation of our work on the chemical constituents of Chinese medicinal plants, we have examined the secondary metabolites present in the bark of *L. rotundifolia* var. *oblongifolia*, since no phytochemical investigation has been done on the species. Two new enol-derived buteno-4-lactones, named rotundifolides A (**1**) and B (**2**), along with four known related butenolactones, lincomolide C (**3**) [13], lincomolide A (**4**) [14], marliolide (**5**) [15], and litsenolide A<sub>1</sub> (**6**) [16] were isolated from the title plant. This paper describes the structure elucidation of the new compounds.

**Results and Discussion.** – Specimens of *L. rotundifolia* var. *oblongifolia* were extracted exhaustively with MeOH, and the MeOH extract was partitioned between H<sub>2</sub>O and organic solvents to afford AcOEt-soluble and BuOH-soluble fractions. The AcOEt extract was further separated by column chromatography and semi-prep. HPLC (see *Exper. Part*) to give the known metabolites **3–6** [13–16] and the new compounds **1** and **2**. The new compounds demonstrated considerable spectral analogy with the co-occurring known butenolides **3–6** [13–16].

Rotundifolide A (**1**), a colorless and optically active oil, exhibited the absorption bands of an OH group (3399 cm<sup>-1</sup>) and an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone (1747 and 1660 cm<sup>-1</sup>) in the IR spectrum. The molecular formula of **1** was determined to be C<sub>17</sub>H<sub>28</sub>O<sub>3</sub> from its HR-EI-MS (*m/z* 280.2042 (*M*<sup>+</sup>)). From analysis of the <sup>1</sup>H- and <sup>13</sup>C-NMR (*Table*) and UV spectra, compound **1** has the same unsaturated  $\beta$ -hydroxy- $\gamma$ -methyl- $\gamma$ -lactone structure as that of co-occurring lincomolide C (**3**) [13]. Nevertheless, the NMR spectra of **1** were somewhat different from those of **3**. On the basis of the spectral evidence, structure **1** was determined to be (5*S*)-3-(dodec-11-enyl)-4-hydroxy-



5-methylfuran-2(5*H*)-one, which was further confirmed by  $^1\text{H}$ ,  $^1\text{H}$  COSY, HMQC, and HMBC (*Fig.*) experiments.




Figure. Selected key HMBC correlations of **1** and **2**

Careful comparison of the  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectra of **1** with those of **3** revealed that the differences were mainly in the butenolactone moiety. The lack of the characteristic olefinic-proton resonance (H–C(1')) and the H–C(4) resonance of **3** together with the appearance of a quaternary C-atom at  $\delta$  177.6 strongly indicated the enol-derived nature of the butenolactone moiety of **1**. In addition, the  $^1\text{H}$ -NMR signals at  $\delta$  4.83 (*m*, H–C(5)) and 1.50 (*d*,  $J = 6.0$  Hz, Me–C(5)) were attributable to a CH bearing a Me group. The presence of an endocyclic butenolactone moiety in **1** was further confirmed by the comparison of  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data of **1** with those of model compound **8** [17]. The absolute configuration at C(5) of **1** was suggested to be (*S*), opposite to that established for a related compound **7**, by comparing the positive  $[\alpha]_{\text{D}}$  value of **1** ( $[\alpha]_{\text{D}} = +11$  (dioxane)) with the

Table. Selected  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Data<sup>a)</sup> of Compounds **1**–**3**

	<b>1</b>		<b>2</b>		<b>3</b>	
	$\delta(\text{H})^{\text{b}}$	$\delta(\text{C})^{\text{c}}$	$\delta(\text{H})^{\text{b}}$	$\delta(\text{C})^{\text{c}}$	$\delta(\text{H})^{\text{b}}$	$\delta(\text{C})^{\text{c}}$
C(2)	–	177.8 (s)	–	176.9 (s)	–	169.8 (s)
C(3)	–	100.7 (s)	–	101.0 (s)	–	130.5 (s)
C(4) or H–C(4)	–	177.6 (s)	–	176.6 (s)	4.80 (d, $J=4.9$ )	67.8 (d)
H–C(5)	4.83 (m)	75.3 (d)	4.82 (m)	74.9 (d)	4.52 (dq, $J=6.6, 4.9$ )	78.6 (d)
Me–C(5)	1.50 (d, $J=6.0$ )	17.8 (q)	1.49 (d, $J=6.0$ )	17.8 (q)	1.44 (d, $J=6.6$ )	14.0 (q)
H–C(1') or CH <sub>2</sub> (1')	2.19 (t, $J=6.1$ )	31.8 (t)	2.18 (m)	31.9 (t)	6.94 (t, $J=7.8$ )	147.8 (d)
CH <sub>2</sub> (2')	–	–	–	–	2.39 (dt, $J=7.8$ )	32.0 (t)
CH <sub>2</sub> (10')	2.02 (m)	33.7 (t)	2.18 (m)	18.3 (t)	2.01 (m)	33.8 (t)
C(11') or H–C(11')	5.79 (ddt, $J=6.6,$ 10.2, 17.0)	139.1 (d)	–	84.7 (s)	5.78 (ddt, $J=6.6,$ 10.2, 17.0)	139.2 (d)
H–C(12') or CH <sub>2</sub> (12')	4.98 (dd, $J=1.6, 17.0,$ 4.92 (br. d, $J=10.2$ ))	114.0 (t)	1.93 (s)	68.0 (d)	4.97 (dd, $J=1.7, 17.0,$ 4.91 (br. d, $J=10.2$ ))	114.1 (t)

<sup>a)</sup> Bruker DRX-400 spectrometer; measured in  $\text{CDCl}_3$ ; chemical shifts in  $\delta$  relative to the  $\text{CDCl}_3$  ( $\delta$  77.0) and residual  $\text{CHCl}_3$  signals ( $\delta$  7.26) as internal standard, respectively; assignments by analysis of 1D and 2D NMR spectra. <sup>b)</sup> Unassigned  $\text{CH}_2$  protons contributed to an intense signal at  $\delta$  1.25–1.30. <sup>c)</sup> The  $\text{CH}_2$  C-atoms not assigned specifically contributed to an intense signal centered at  $\delta$  29.8.

negative one of **7** ( $[\alpha]_{\text{D}} = -29.8$  (dioxane)) [18]. Moreover, the same positive  $[\alpha]_{\text{D}}$  sign of **1** as those of the closely related compounds **9** and **10** [19] further supported the assigned (5*S*) configuration.

Rotundifolide B (**2**), a colorless oil, gave a quasi-molecular ion at  $m/z$  277 ( $[M - \text{H}]^-$ ) in its ESI-MS, corresponding to a molecular formula  $\text{C}_{17}\text{H}_{26}\text{O}_3$ , of two mass units less than that of **1**. The  $^1\text{H}$ -NMR spectrum of **2** exhibited similarities with that of compound **1**. In fact, compound **2** differs from **1** only by the presence of a terminal ethynyl group ( $\delta(\text{H})$  1.93 (s, H–C(12')),  $\delta(\text{C})$  68.0 (d) and 84.7 (s)) instead of a terminal C=C bond in the  $\text{C}_{12}$  side chain. As in the case of **1**, the configuration at C(5) was assigned to be (5*S*).

The new enol-derived butenolactones **1** and **2** are encountered for the first time in Lauraceae plants although their corresponding deoxy derivatives **9** and **10** have been isolated from the leaves of three species of *Hortonia* (family Monimiaceae) very recently [19]. In particular, it is of interest that both **9** and **10** were reported to have potent mosquito larvicidal activity against the second instar larvae of *Aedes aegypti* [19]. It, thus, seems desirable to assay the butenolactones **1**–**6** for the same biological properties.

In addition, bioactivity screenings revealed that rotundifolide A (**1**) exhibited significant *in vitro* inhibitory activity ( $IC_{50} = 9.2\mu\text{M}$ ) against the enzyme protein tyrosine phosphatase-1B (PTP1B), a tyrosine phosphatase that has been implicated as a key target for type-II diabetes [20].

This work was financially supported by the grant 30125044 from the National Natural Science Foundation for Outstanding Youth. The authors are grateful to Prof. F.-W. Xin, South China Institute of Botany, Chinese

Academy of Sciences, for identification of the plant material. The NMR and the mass spectra were obtained from the 'SIMM-NMR, MS Services'. The staff of both services are gratefully acknowledged.

### Experimental Part

*General.* Column chromatography (CC): commercial silica gel (*Qing Dao Hai Yang Chemical Group Co.*; 100–200 and 200–300 mesh). Anal. TLC: precoated silica gel plates (*Yan Tai Zi Fu Chemical Group Co.*; *G60 F-254*). Reversed-phase HPLC: *Agilent 1100* liquid chromatograph, equipped with an *Agilent 1100-G1314A* variable-wavelength detector; semi-prep. *Develosil ODS-5* column (5  $\mu\text{m}$ ; 9.6 mm (i.d.)  $\times$  25 cm);  $t_{\text{R}}$  in min. Optical rotation: *Perkin-Elmer 341* polarimeter. UV Spectra: *Varian-Cary 300-Bio* spectrophotometer;  $\lambda_{\text{max}}$  (log  $\epsilon$ ) in nm. IR Spectra: *Nicolet Magna-FT-IR-750* spectrometer;  $\nu_{\text{max}}$  in  $\text{cm}^{-1}$ .  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Spectra: *Bruker DRX-400* spectrometer at 400 MHz for  $^1\text{H}$  and 100 MHz for  $^{13}\text{C}$ ; chemical shifts  $\delta$  in ppm, with residual  $\text{CHCl}_3$  ( $\delta(\text{H})$  7.26,  $\delta(\text{C})$  77.0) as internal standard, coupling constants  $J$  in Hz; assignments supported by  $^1\text{H}$ ,  $^1\text{H}$ -COSY, HMQC, and HMBC experiments. EI-MS and HR-EI-MS: *MAT-95* mass spectrometer; in  $m/z$  (rel. %). ESI-MS and HR-ESI-MS: *Q-TOF-Micro* LC-MS-MS mass spectrometer; in  $m/z$ .

*Plant Material.* The sample examined was collected from the Guangdong Province of China in August 2001 and identified by Prof. F.-W. Xin of the South China Institute of Botany, Chinese Academy of Sciences. A voucher specimen (no. PL02-5) is deposited in the Herbarium of the Institute of Materia Medica, SIBS-CAS.

*Extraction and Purification.* The powdered bark of *L. rotundifolia* var. *oblongifolia* (1 kg) was repeatedly extracted with MeOH (9 l) at r.t. The extract was evaporated to give a brown syrup (132 g), which was partitioned with solvents into AcOEt-soluble (65 g) and BuOH-soluble (20 g) fractions, respectively. The AcOEt-soluble portion was subjected to CC (*Sephadex LH-20*,  $\text{CHCl}_3/\text{MeOH}$  1:1): *Fractions 1–15*. *Fr. 5* (110.3 mg) was subjected to CC (silica gel, petroleum ether/ $\text{Et}_2\text{O}$  gradient): mixture of lactones (*Fr. 5.1*; 20.6 mg), crude **1** (*Fr. 5.2*; 15.2 mg), and crude **2** (*Fr. 5.3*; 10.6 mg). *Fr. 5.1* was further separated by prep. HPLC ( $\text{MeOH}/\text{H}_2\text{O}$  8:2, flow rate 2 ml/min): **3** (4.6 mg;  $t_{\text{R}}$  20.9), **5** (3.2 mg;  $t_{\text{R}}$  21.8), **6** (2.8 mg;  $t_{\text{R}}$  22.5), and **4** (1.8 mg;  $t_{\text{R}}$  31.7). The crude **1** and **2** were each resubjected to CC (silica gel, petroleum ether/ $\text{Et}_2\text{O}$  4:6): pure **1** (10.0 mg) and **2** (8.2 mg).

*Rotundifolide A* (= (5*S*)-3-(*Dodec-11-enyl*)-4-hydroxy-5-methylfuran-2(5*H*)-one; **1**): Colorless oil.  $[\alpha]_{\text{D}}^{25} = +11$  ( $c = 0.25$ , dioxane). UV (EtOH): 210 (4.2). IR (KBr): 3399, 2923, 2850, 1747, 1660, 1641, 1072, 912.  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR: *Table*. ESI-MS: 279 ( $[M - \text{H}]^-$ ). EI-MS: 280 (15,  $M^+$ ), 262 (8), 128 (92), 115 (100), 98 (28), 69 (32), 55 (56). HR-EI-MS: 280.2042 ( $\text{C}_{17}\text{H}_{28}\text{O}_3^+$ ; calc. 280.2038).

*Rotundifolide B* (= (5*S*)-3-(*Dodec-11-ynyl*)-4-hydroxy-5-methylfuran-2(5*H*)-one; **2**): Colorless oil.  $[\alpha]_{\text{D}}^{25} = +21.7$  ( $c = 0.20$ , dioxane). UV (EtOH): 210 (4.2). IR (KBr): 3309, 2923, 2850, 2118, 1757, 1660, 1465, 1071, 721, 636.  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR: *Table*. ESI-MS: 277 ( $[M - \text{H}]^-$ ).

### REFERENCES

- [1] X.-H. Yan, F.-X. Zhang, H.-H. Xie, X.-Y. Wei, *J. Trop. Subtrop. Botany* **2000**, *2*, 171.
- [2] D. S. Bhakuni, S. Gupta, *Planta Med.* **1983**, *48*, 52.
- [3] S. Tewari, D. S. Bhakuni, M. Dhar, *Phytochemistry* **1972**, *11*, 1149.
- [4] R. C. Rastogi, N. Borthakur, *Phytochemistry* **1980**, *19*, 998.
- [5] H. S. Mohan, H. D. Pathak, *Nat. Appl. Sci. Bull.* **1975**, *27*, 95.
- [6] J. A. Lopez, W. Barillas, G. L. Jorge, J. Gomez Laurito, F. T. Lin, A. J. Alrehaily, M. H. M. Sharaf, P. L. Schiff, *Planta Med.* **1995**, *61*, 198.
- [7] E. H. Hakim, S. A. Achmad, E. L. Ghisalberti, D. C. R. Hockless, A. H. White, *Aust. J. Chem.* **1993**, *46*, 1355.
- [8] S. A. Achmad, E. L. Ghisalberti, E. L. Hakim, L. Makmur, M. Manurung, *Phytochemistry* **1992**, *31*, 2153.
- [9] H. Tanaka, T. Nakamura, K. Ichino, K. Ito, T. Tanaka, *Phytochemistry* **1990**, *29*, 857.
- [10] K. P. Padmakumari, C. S. Narayannan, *J. Essent. Oil Res.* **1992**, *4*, 87.
- [11] L. Q. N. Huang, M.-L. Shu, P.-R. Chen, *Nat. Prod. Res. Dev.* **1994**, *6*, 1.
- [12] N. K. Hart, S. R. Johns, J. A. Lambertson, J. W. Loder, A. Moorhouse, A. A. Sioumis, T. K. Smith, *Aust. J. Chem.* **1969**, *22*, 2259.
- [13] I.-L. Tsai, C.-H. Hung, C.-Y. Duh, I.-S. Chen, *Planta Med.* **2002**, *68*, 142.
- [14] I.-L. Tsai, C.-H. Hung, C.-Y. Duh, I.-H. Chen, W.-Y. Lin, I.-S. Chen, *Planta Med.* **2001**, *67*, 856.

- [15] B. M. G. Claros, A. J. R. da Silva, M. L. A. A. Vasconcellos, A. P. P. de Brito, G. G. Leitao, *Phytochemistry* **2000**, *55*, 859.
- [16] K. Takeda, K. Sakurawi, H. Ishii, *Tetrahedron* **1972**, *28*, 3757.
- [17] Y.-W. Guo, M. Gavagnin, E. Mollo, E. Trivellone, G. Cimino, *J. Nat. Prod.* **1999**, *62*, 1194.
- [18] C. Juan, V. Martinez, Y. Massayoshi, R. G. Otto, *Phytochemistry* **1981**, *20*, 459.
- [19] R. Ratnayake, V. Karunaratne, B. M. R. Bandara, V. Kumar, J. K. Macleod, P. Simmonds, *J. Nat. Prod.* **2001**, *64*, 376.
- [20] T. N. Doman, S. L. McGovern, B. J. Witherbee, T. P. Kasten, R. Kurumbail, W. C. Stallings, D. T. Connolly, B. K. Shoichet, *J. Med. Chem.* **2002**, *45*, 2213.

*Received November 22, 2004*